

BEST AVAILABLE COPY

Attorney Docket No.: 4318.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 7527

Serial No.: 09/902,188

Group Art Unit: 1751

Filed: July 10, 2001

Examiner: To be assigned

For: Amylase Variants

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is a Preliminary Amendment for the above-identified application.

The fee for claims has been calculated as shown below:


Total: $18 - 20 = 0 \times 18 = \0 Independent: $4 - 3 = 1 \times 84 = \$84$

Total additional fee for claims required is \$84.

Please charge the claim fees, estimated to be \$84, or any fee due and owing to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: December 13, 2001


Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123FAX RECEIVED
DEC 13 2001
GROUP 1700
OFFICIALRECEIVED
DEC 27 2001
TC 1700

Telefax

novozymes



#7B
NEW

BEST AVAILABLE COPY

No. of pages incl. this: 8

Telefax no.: 703-872-9310

To: USPTO

CC:

From: Jason Garbell

FAX RECEIVED
DEC 13 2001
GROUP 1700

OFFICIAL

Message:

Preliminary Amendment for 09/902,188

RECEIVED
DEC 27 2001
TC 1700

Confidential information may be contained in this fax and is intended only for the use of the addressee. If you are not the addressee, please do not copy or deliver this to anyone else. If you receive this telefax by mistake, please telephone the sender. Thank you.

Novozymes
North America, Inc.
Patents

405 Lexington Av.,
Suite 6400
New York

Telephone:
(212)-867-0123
Telefax:
(212)-867-0298

Web:
www.novozymes.com

Attorney Docket No.: 4318.224-US

BEST AVAILABLE COPY

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 7527

Serial No.: 09/902,188

Group Art Unit: 1751

Filed: July 10, 2001

Examiner: To be assigned

For: Amylase Variants

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Preliminary Amendment

was sent to the United States Patent and Trademark Office by telefax to Group Art Unit 1751, fax number (703) 872-9310.

Respectfully submitted,

Date: December 13, 2001



Jason Garbell
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

FAX RECEIVED
DEC 13 2001
GROUP 1700
OFFICIAL

RECEIVED
DEC 27 2001
TC 1700

BEST AVAILABLE COPY

Attorney Docket N .: 4318.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Blsgaard-Frantzen et al.

Confirmation No: 7527

Serial No.: 09/902,188

Group Art Unit: 1751

Filed: July 10, 2001

Examiner: To be assigned

For: Amylase Variants

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 30-49.

Please add the following new claims:

50. A variant of a parent alpha-amylase enzyme, wherein said parent alpha-amylase has an amino acid sequence which has at least 80% homology to SEQ ID NO:3, and wherein said variant comprises deletions at positions equivalent to positions 179 and 180 in SEQ ID NO:3 (using SEQ ID NO:3 for numbering).

51. The variant of claim 50, wherein said parent alpha-amylase has an amino acid sequence which has at least 85% homology to SEQ ID NO:3.

52. The variant of claim 50, wherein said parent alpha-amylase has an amino acid sequence which has at least 90% homology to SEQ ID NO:3.

53. The variant of claim 50, wherein said parent alpha-amylase has an amino acid sequence which has at least 95% homology to SEQ ID NO:3.

RECEIVED
DEC 27 2001
TC 1700